American Pharmaceutical Sinks After Hours
American Pharmaceutical Partners (APPX) doesn't expect to get approval for Ceftriaxone for injection in the near term, citing information the drug company received this week from a raw material supplier that was inspected by the Food and Drug Administration.
The company said the development doesn't affect any currently marketed products, and American Pharmaceutical said its previous guidance of 8% to 10% annual growth in its core generic injectable business remains unchanged.
Shareholders were concerned however, sending American Pharmaceutical down $4.85, or 11%, to $40.70 in extended trading.
American Pharmaceutical, of Schaumburg, Ill., develops and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV